AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3176957
Drug: No infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No infusion analgesia in the second stage of labor (group A)
Trial: 30180054
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no steroid)
Trial: 21138388
Drug: Intra-articular steroid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular steroid injection (triamcinolone acetonide)
Trial: 16191133
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement plus behavioral treatment
Trial: 12826989
Drug: Meprobamate (2,400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meprobamate (2,400 mg)
Trial: 12826989
Drug: Butabarbital (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Butabarbital (400 mg)
Trial: 3516077
Drug: Indomethacin (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (0.2 mg/kg)
Trial: 1670723
Drug: Remission reinforcement
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remission reinforcement therapy (teniposide, cytarabine, high‐dose methotrexate)
Trial: 1670723
Drug: Four pairs
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four pairs of drugs rotated weekly or every 6 weeks
Trial: 30959514
Drug: GHB (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHB (50 mg/kg p.o.)
Trial: 27128712
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2)) every 14 days for four cycles
Trial: 27128712
Drug: Doxorubicin (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2))
Trial: 19694630
Drug: Venlafaxine monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine monotherapy for 12 weeks
Trial: 18022033
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg per day
Trial: 10745071
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day gossypol
Trial: 10745071
Drug: gossypol treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gossypol treatment
Trial: 18630536
Drug: Medication group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication group (oral administration of Betaloc and Oryzanol)
Trial: 29273130
Drug: Birch subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch subcutaneous allergen immunotherapy (AIT) for 24 months
Trial: 29273130
Drug: Birch subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Birch subcutaneous allergen immunotherapy (AIT)
Trial: 26562368
Drug: Early HepB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early HepB (administered within a few hours after birth)
Trial: 26562368
Drug: Late HepB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late HepB (administered after the repeat CRP)
Trial: 24934774
Drug: 20mg diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg diazepam nasal spray (NS)
Trial: 24934774
Drug: 20mg diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg diazepam rectal gel (RG)
Trial: 24934774
Drug: Both intranasal
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intranasal and rectal treatments
Trial: 9802271
Drug: Self-supervised treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-supervised treatment (retreatment patients)
Trial: 9802271
Drug: Direct observation
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct observation (DO) treatment (retreatment patients)
Trial: 31419597
Drug: Linguistically‐based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linguistically‐based treatment of passive sentence production and comprehension (N = 14, treatment group)
Trial: 24373522
Drug: Expectation-induced placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectation-induced placebo (wound gel)
Trial: 24373522
Drug: Non-active gel
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active gel (control group)
Trial: 16454838
Drug: Rifaximin 400
RxNorm normalized name: Rifaximin 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifaximin 400 mg b.i.d.
Trial: 8545745
Drug: Hypoxoside (1,200‐3,200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypoxoside (1,200‐3,200 mg standardized Hypoxis plant extract per day divided in 3 doses)
Trial: 2322638
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release capsules of 120 mg administered every 12 h
Trial: 27348402
Drug: Breathing a
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Breathing a hyperoxic gas mixture with a constant fraction of 60% inhaled oxygen during exercise training
Trial: 27894777
Drug: Long-acting-release octreotide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting-release octreotide (20 mg intramuscularly, 2 doses, 4 weeks before and on the day of surgery)
Trial: 21488717
Drug: Sensor-augmented pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensor-augmented pump (SAP) therapy
Trial: 15350001
Drug: Molecular adsorbents
RxNorm normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Molecular adsorbents recirculating system (MARS) therapy over 7 days
Trial: 23341981
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy (SMT) alone
Trial: 15350001
Drug: MARS therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MARS therapy
Trial: 11598598
Drug: Calcium-fortified cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-fortified cereal (156 mg/serving)
Trial: 11598598
Drug: Low-calcium cereal
RxNorm normalized name: Dianeal Low Calcium 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-calcium cereal (39 mg/serving)
Trial: 30635055
Drug: silybin-phosphatidylcholine complex
RxNorm normalized name: silybin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: silybin-phosphatidylcholine complex (45 mg)
Trial: 18823212
Drug: Aural presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aural presentation of nonwords with unattested onsets (e.g., bnif, bdif, lbif)
Trial: 10673994
Drug: Infusional 5-FU
RxNorm normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Infusional 5-FU therapy (B1, B2, B3 regimens)
Trial: 27402817
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of atorvastatin
Trial: 18287255
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa once weekly
Trial: 11127783
Drug: Complementary Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complementary Medicine (CM)
Trial: 9367398
Drug: IVIG infusions
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG infusions during placebo phase
Trial: 9367398
Drug: IVIG infusions
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG infusions during nhuIL-2 treatment phase
Trial: 26538428
Drug: Genotype-guided dosing
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genotype-guided dosing (PGx)
Trial: 22685047
Drug: 7 g
RxNorm normalized name: Vaporizer 1.7 gallon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 g dark chocolate daily for 7 weeks
Trial: 17875243
Drug: PR-melatonin (Circadin*
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-melatonin (Circadin* 2 mg), one tablet per day at 2 hours before bedtime
Trial: 17875243
Drug: PR-melatonin (Circadin*
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PR-melatonin (Circadin* 2 mg)
Trial: 12090325
Drug: Prednisolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (40 mg/day) and azathioprine (100 mg/day) for four months
Trial: 1370924
Drug: t‐PA (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA (60 mg in the first hour and a maintenance infusion of 13.3 mg/hr for 3 hours)
Trial: 6376145
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glipizide (meal + glipizide)
Trial: 27620884
Drug: Surgical glove
RxNorm normalized name: Astrapro Surgical Gloves
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical glove (SG) compression therapy
Trial: 3302924
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 mg/kg every six hours)
Trial: 23959376
Drug: Desensitizing agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desensitizing agent (5% potassium nitrate, 2% sodium fluoride)
Trial: 18402848
Drug: Unlimited free
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unlimited free emergency contraceptive pills (ECPs) in advance of need
Trial: 18402848
Drug: Standard access
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard access to emergency contraceptive pills (ECPs)
Trial: 15806544
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 microg/kg/day) plus antibiotics
Trial: 15806544
Drug: Antibiotics without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotics without G-CSF
Trial: 3071619
Drug: Nilvadipine 4
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 4 mg 3 times a day
Trial: 3071619
Drug: Nilvadipine 4
RxNorm normalized name: nilvadipine
DrugBank: Nilvadipine (DB06712)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine 4 mg twice a day
Trial: 11230635
Drug: Gadobutrol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gadobutrol (1.0 mol/L) injected intravenously at doses of 0.1 or 0.3 mmol/kg
Trial: 29873107
Drug: Food Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Food Insulin Index
Trial: 19089749
Drug: Coffeeberry (CB)
RxNorm normalized name: BroveX CB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffeeberry (CB) supplementation at a dose of 800 mg per day for 4 weeks
Trial: 14602757
Drug: Nateglinide 120
RxNorm normalized name: nateglinide 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nateglinide 120 mg
Trial: 7479216
Drug: No erythropoietin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No erythropoietin treatment
Trial: 453783
Drug: Orally given
RxNorm normalized name: TITANIUM DIOXIDE 7.75 g in 100 mL / ZINC OXIDE 10 g in 100 mL TOPICAL CREAM [Give Me Shade Sunscreen Broad Spectrum SPF 30]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally given analgesic-spasmolytic combination preparation (Group II)
Trial: 453783
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no medication, Group III)
Trial: 25240532
Drug: Canakinumab 10
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Canakinumab 10 mg/kg
Trial: 8912230
Drug: ipsapirone (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone (20 mg)
Trial: 29153975
Drug: Empirical antimicrobial
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empirical antimicrobial therapy (EAT) withdrawn after 72 hours of apyrexia plus clinical recovery.
Trial: 23689809
Drug: Metronidazole (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (15 to 20 mg/kg per day for 3 months)
Trial: 19229497
Drug: CBT SL-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT SL-5 lotion (containing cell-free culture supernatant of E. faecalis SL-5)
Trial: 8255556
Drug: Amphetamine administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amphetamine administration (oral and intramuscular)
Trial: 3518724
Drug: Ibopamine (200-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibopamine (200-300 mg single oral dose)
Trial: 30742244
Drug: Anti-TNF-α treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-TNF-α treatment (group B)
Trial: 30742244
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) and sulfasalazine (SSZ) (group A)
Trial: 20851549
Drug: 3-h infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-h infusion of imipenem/cilastatin
Trial: 12887823
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Ramipril and Losartan
Trial: 3823619
Drug: Bezafibrate (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (200 mg t.i.d.)
Trial: 6740281
Drug: Duck embryo
RxNorm normalized name: Duck
DrugBank: Duck (DB10610)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duck embryo rabies vaccine (DEV), administered according to the prescribed schedule (14 initial inoculations and 3 boosters)
Trial: 25237116
Drug: CBD 300
RxNorm normalized name: MENTHOL, UNSPECIFIED FORM 10 g in 100 g / CAMPHOR (SYNTHETIC) 3 g in 100 g TOPICAL CREAM [ETERNAL SPIRIT BEAUTY PAINLESS WITH CBD 3000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD 300 mg/day
Trial: 31560051
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Vancomycin (OVP) 125 mg once daily for 5 days post-systemic antibiotics
Trial: 31560051
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Vancomycin (OVP)
Trial: 24794368
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (4 mg/kg/d for 2 weeks) and oral prednisolone (2 mg/kg/d for 2 weeks) followed by a tapering protocol for 9 weeks
Trial: 24794368
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone and oral prednisolone
Trial: 27262892
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy of the involved shoulder for 10 weeks
Trial: 27262892
Drug: Exercise therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise therapy of the uninvolved shoulder for 10 weeks (Control group)
Trial: 20334449
Drug: Individualized antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized antithrombotic therapy
Trial: 12243609
Drug: Selective serotonin-reuptake
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin-reuptake inhibitors (SSRIs)
Trial: 8565089
Drug: 6-month short-course
RxNorm normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-month short-course chemotherapy
Trial: 24194532
Drug: Intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive insulin therapy (IT) for 2 weeks
Trial: 17980093
Drug: Combined 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined 0.5% moxifloxacin and 0.1% dexamethasone formulation (Vigadexa)
Trial: 7595165
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups after 64-week treatment period
Trial: 2147859
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) 25-50 mg/day + ethinyl-estradiol (EE) 20-30 micrograms/day
Trial: 2147859
Drug: SPL +
RxNorm normalized name: Salmeterol plus fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPL + bromocriptine (2.5-5 mg/day)
Trial: 2147859
Drug: Cyproterone acetate
RxNorm normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyproterone acetate (CPA) alone or associated with tamoxifen (100 mg + 100 mg/day)
Trial: 24132190
Drug: Warfarin (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (in patients with prior MI)
Trial: 19359647
Drug: Blood pressure
RxNorm normalized name: Blood Pressure Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blood pressure lowering treatment (Perindopril)
Trial: 12577435
Drug: Qingwei Zhitong
RxNorm normalized name: METHYL SALICYLATE 13 g / MENTHOL 9 g / CAMPHOR (SYNTHETIC) 11 g TOPICAL PATCH [KGS Zhitong Gao Medicated Plaster Extra Strength]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qingwei Zhitong pill (QWZTP)
Trial: 12577435
Drug: Sifangwei tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sifangwei tablet
Trial: 24152974
Drug: DelpHi-Intervention conducted
RxNorm normalized name: Delphinium staphisagria preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DelpHi-Intervention conducted by Dementia Care Managers (DCMs) with dementia-specific training; details on dosage and duration not specified.
Trial: 19216048
Drug: Family‐based cognitive‐behavioral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family‐based cognitive‐behavioral therapy (FCBT)
Trial: 1504111
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg yohimbine
Trial: 30972871
Drug: Dr. Wolff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dr. Wolff Gel (test gel)
Trial: 30972871
Drug: Biotene (control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene (control gel)
Trial: 19858419
Drug: CRT on
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRT on (active therapy)
Trial: 9151927
Drug: YNK-01 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YNK-01 at 200 mg/d
Trial: 9151927
Drug: YNK-01 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YNK-01 at 300 mg/d
Trial: 7476236
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with parasite derived antigen (94‐67 KD)
Trial: 7476236
Drug: Antimonial therapy
RxNorm normalized name: antimony
DrugBank: Antimony (DB13110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimonial therapy
Trial: 1282182
Drug: Nicorandil (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicorandil (30 mg)
Trial: 2525330
Drug: Diltiazem (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (low-dose 60 mg)
Trial: 28095801
Drug: Small‐quantity lipid‐based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small‐quantity lipid‐based nutrient supplement (SQ‐LNS)
Trial: 26248034
Drug: Sildenafil citrate®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil citrate® 100 mg for 2-3 times per week in addition to intensive glycemic control
Trial: 19756419
Drug: Thrice-daily dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrice-daily dosing of 200 mg/kg per day ceftazidime
Trial: 15063387
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg lycopene/day (Group A)
Trial: 1569443
Drug: Cisplatin 100
RxNorm normalized name: CISPLATIN 100MG/VIL (PF) INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin 100 mg/m2 plus cyclophosphamide 600 mg/m2
Trial: 1569443
Drug: Carboplatin 300
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2
Trial: 17914351
Drug: Biocompatible dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biocompatible dialysis solutions (B)
Trial: 17914351
Drug: Standard dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dialysis solutions (S)
Trial: 16157429
Drug: Inactivated, trivalent,
RxNorm normalized name: Influenza, adjuvanted, inactivated, trivalent, injectable, preservative free
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated, trivalent, virosome-formulated subunit influenza vaccine (Inflexal V, Berna Biotech, Berne, Switzerland)
Trial: 12881345
Drug: 0.5% levofloxacin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% levofloxacin ophthalmic solution
Trial: 8981915
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (r-hGH; 2.0 IU/d)
Trial: 1536016
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml (2.0 mg) of chymopapain